NOT-CA-01-014: RAPID ACCESS TO PREVENTIVE INTERVENTION DEVELOPMENT

Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health^®


RAPID ACCESS TO PREVENTIVE INTERVENTION DEVELOPMENT    RAPID  - ADDENDUM

Release Date:  June 20, 2001

NOTICE:  NOT-CA-01-014

National Cancer Institute

Investigators are hereby notified that the receipt date for requests 
for RAPID resources has been changed to October 1, 2001.  
Investigators are further notified that the contact person and web 
site for the RAPID program have changed, see 
http://cancer.gov/rapid.

The Rapid Access to Preventive Intervention Development (RAPID) 
program makes available to academic investigators the preclinical 
and early clinical drug development contract resources of NCI’s 
Division of Cancer Prevention. The goal of the RAPID program is the 
expeditious movement of novel molecules and concepts from the 
laboratory to the clinic for clinical trials of efficacy.  RAPID 
will assist investigators who submit successful requests by 
providing any (or all) of the preclinical and phase 1 clinical 
developmental requirements for phase 2 clinical efficacy trials. 
These include, for example, preclinical pharmacology, toxicology, 
and efficacy studies, bulk supply, GMP manufacturing, and 
formulation, and regulatory and IND support and phase 1 clinical 
studies.  Suitable types of agents for RAPID may range from single 
chemical or biological entities to defined complex mixtures with the 
potential to prevent, reverse, or delay carcinogenesis.  For more 
detailed information, please visit the RAPID web site, 
http://cancer.gov/rapid.

INQUIRIES:

Inquiries are encouraged, and the opportunity to clarify issues or 
answer questions is welcome.  Inquires should be sent to:

RAPID Program
Attn:  Emilia A. Richichi, Ph.D.
Chemopreventive Agent Development Research Group
Division of Cancer Prevention, NCI
Executive Plaza North, Room 2117
6130 Executive Blvd., Rockville, MD 20852 (overnight mail)
9000 Rockville Pike, Bethesda, MD 20892 (regular mail)
Telephone:  (301) 594-1165
Fax:  (301) 402-0553
Email:  [email protected]
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices